Kerry’s primary focus is patent drafting, prosecution, opposition and appeals before the European Patent Office but he also has extensive experience in all phases of foreign patent prosecution. He also provides FTO/infringement advice.
He undertakes work in a wide variety of technology areas including pharmaceuticals, biologicals, chemistry and biochemistry, microbiology, cell and molecular biology, immunology and medical devices.
Kerry has a particular interest in food technology, including alt proteins, fermentation, cultured meat and cellular agriculture, food ingredients, food feed and food enzymology, advising a variety of companies at various stages of development on IP strategies to attract funding or IP due diligence in preparing for acquisition, and advising on proactive attacking or defensive strategies in relation to third party IP.
Kerry acts for a wide range of clients including start-ups and investors, research institutions, universities and spin-outs, mid-size companies and international corporations.
Kerry works with private equity and venture capital investors to assess and mitigate IP risks associated with an investment. Kerry particularly enjoys working with investee companies to develop IP strategies which support the business plan and to secure commercially relevant IP whether that be to secure funding or increase growth and market share.
Molecular and Cellular Biochemistry, University of Oxford
Certificate in Intellectual Property Law, University of London
May 18th 2021
December 2nd 2020
November 20th 2020
September 11th 2020
September 2nd 2020
Medical Technology Ireland Conference 2022 will be held on 21-22 September at the Galway Racecource. Medical Technology Ireland is a new high-profile National and International event attracting global suppliers to …Event details
Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …Read article
Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder . …Read article
Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …Read article
Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …Read article
Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …Read article
After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …Event details
HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …Event details
If you would like to discuss how HGF could help you, contact one of our IP specialists.